Over the past several decades, messenger RNA (mRNA) vaccines have progressed from a
scepticism-inducing idea to clinical reality. In 2020, the COVID-19 pandemic catalysed the …

The increasing number of approved nucleic acid therapeutics demonstrates the potential to
treat diseases by targeting their genetic blueprints in vivo. Conventional treatments …

Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

The success of the first licensed mRNA-based vaccines against COVID-19 has created a
widespread interest on mRNA technology for vaccinology. As expected, the number of …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

Highlights•First malaria vaccine RTS, S induces anti-sporozoite antibodies to protect
children.•Whole-sporozoite vaccines induce T cells and antibodies and confer field …

The world raced to develop vaccines to protect against the rapid spread of SARS-CoV-2
infection upon the recognition of COVID-19 as a global pandemic. A broad spectrum of …

Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease
transmitted by infected mosquitoes. Malaria remains a major global health challenge …

In recent years, vaccine development using ribonucleic acid (RNA) has become the most
promising and studied approach to produce safe and effective new vaccines, not only for …

Malaria is a deadly disease responsible for between 550,000 and 627,000 deaths annually.
There is a pressing need to develop vaccines focused on malaria elimination. The complex …